# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung...
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $45 pr...
HC Wainwright & Co. analyst Mitchell Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and raises the price ...
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also rais...